Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
JAMA Dermatol ; 160(7): 769-770, 2024 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-38776072

RESUMEN

This case report describes nonblanching, confluent, purpuric macules and patches on the palmoplantar and dorsal finger surfaces and red to grayish papulovesicles on the dorsal hands and feet, limbs, trunk, and face.


Asunto(s)
Enfermedad de Boca, Mano y Pie , Humanos , Enfermedad de Boca, Mano y Pie/diagnóstico , Enfermedad de Boca, Mano y Pie/virología , Masculino , Enterovirus/aislamiento & purificación , Femenino , Enterovirus Humano A/aislamiento & purificación
2.
Clin Exp Dermatol ; 48(12): 1405-1408, 2023 11 16.
Artículo en Inglés | MEDLINE | ID: mdl-37668311

Asunto(s)
Mano , Úlcera , Humanos
3.
Genes (Basel) ; 14(7)2023 06 23.
Artículo en Inglés | MEDLINE | ID: mdl-37510231

RESUMEN

Pattern hair loss can occur in both men and women, and the underlying molecular mechanisms have been continuously studied in recent years. Male androgenetic alopecia (M-AGA), also termed male pattern hair loss, is the most common type of hair loss in men. M-AGA is considered an androgen-dependent trait with a background of genetic predisposition. The interplay between genetic and non-genetic factors leads to the phenotype of follicular miniaturization. Although this similar pattern of phenotypic miniaturization can also be found in female pattern hair loss (FPHL), the corresponding genetic factors in M-AGA do not account for the phenotype in FPHL, indicating that there are different genes contributing to FPHL. Therefore, the role of genetic factors in FPHL is still uncertain. Understanding the genetic mechanism that causes FPHL is crucial for the future development of personalized treatment strategies. This review aims to highlight the differences in the ethnic prevalence and genetic background of FPHL, as well as the current genetic research progress in nutrition, Wnt signaling, and sex hormones related to FPHL.


Asunto(s)
Alopecia , Andrógenos , Masculino , Femenino , Humanos , Alopecia/genética , Predisposición Genética a la Enfermedad , Fenotipo , Vía de Señalización Wnt/genética
8.
Photodermatol Photoimmunol Photomed ; 36(4): 257-262, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-32022939

RESUMEN

Phototherapy is the most commonly used modality for repigmenting vitiligo. Currently, UVB emitting devices, including narrow-band UVB (NBUVB) and excimer laser/light, are considered as the treatment of choice. While emitting wavelengths at close proximity, excimer lights emit higher irradiance (HI; W/m2 ) compared to NBUVB. Clinical reports have shown that excimer light is more efficacious in treating vitiligo compared to NBUVB, and we demonstrated that irradiance plays a critical role in promoting melanoblasts differentiation. UVB radiation from the sun is closely associated with photocarcinogenesis of the skin. Sunscreens were used to protect the skin by reducing UVB irradiance (low irradiance (LI) UVB). Sunscreen use was associated with skin cancer reduction in clinical trials. Paradoxically, sunscreen use was associated with increased sunburn episodes in the real-world settings. It was shown that UVB-induced sunburn depends on fluence (J/m2 ) but not irradiance of UVB radiation. We investigated the significance of irradiance in the context of UVB-induced carcinogenesis of the skin. For mice receiving equivalent fluence of UVB exposure, the LIUVB-treated mice showed earlier tumor development, larger tumor burden, and more epidermal keratinocytes harboring mutant p53 as compared to their HIUVB-treated counterparts. These results suggested that at equivalent fluence, LIUVB radiation has more photocarcinogenic potential on the skin compared to its HI counterpart. Since development of sunburn with or without sunscreen use indicates that certain threshold of UVB fluence has been received by the skin at LI and HI, respectively, sunburn episodes with sunscreen use (LIUVB) are more damaging to the skin compared to that without sunscreen (HIUVB) application. In summary, since irradiance plays an important role determining the biological effects of UVB radiation on the skin, future related studies should take this critical parameter into consideration.


Asunto(s)
Carcinogénesis/efectos de la radiación , Neoplasias Cutáneas/etiología , Rayos Ultravioleta/efectos adversos , Terapia Ultravioleta , Vitíligo/radioterapia , Animales , Humanos , Láseres de Excímeros/uso terapéutico , Ratones , Neoplasias Cutáneas/prevención & control , Protectores Solares/uso terapéutico , Terapia Ultravioleta/efectos adversos , Terapia Ultravioleta/métodos
11.
Arch Phys Med Rehabil ; 98(1): 36-42, 2017 01.
Artículo en Inglés | MEDLINE | ID: mdl-27666156

RESUMEN

OBJECTIVE: To compare the effects of 2 different injection sites of low doses of botulinum toxin type A with steroid in treating lateral epicondylalgia. DESIGN: Double-blind, randomized, active drug-controlled trial. SETTING: Tertiary medical center. PARTICIPANTS: Patients with lateral epicondylalgia for >6 months were recruited from a hospital-based outpatient population (N=26). A total of 66 patients were approached, and 40 were excluded. No participant withdrew because of adverse effects. INTERVENTIONS: Patients were randomly assigned into 3 groups: (1) botulinum toxin epic group (n=8), who received 20U of botulinum toxin injection into the lateral epicondyle; (2) botulinum toxin tend group (n=7), who received 20U of botulinum toxin injected into tender points of muscles; and (3) steroid group (n=11), who received 40mg of triamcinolone acetonide injected into the lateral epicondyle. MAIN OUTCOME MEASURES: A visual analog scale, a dynamometer, and the Patient-Rated Tennis Elbow Evaluation were used to evaluate the perception of pain, maximal grip strength, and functional status, respectively. Outcome measures were assessed before intervention and at 4, 8, 12, and 16 weeks after treatment. The primary outcome measure was a visual analog scale. RESULTS: At 4 weeks after injection, the steroid group was superior to the botulinum toxin tend group in improvement on the visual analog scale (P=.006), grip strength (P=.03), and Patient-Rated Tennis Elbow Evaluation (P=.02). However, these differences were not observed at the 8-, 12-, and 16-week follow-up assessments. There was no significant difference between the steroid and botulinum toxin epic groups. CONCLUSIONS: Injections with botulinum toxin and steroid effectively reduced pain and improved upper limb function in patients with lateral epicondylalgia for at least 16 weeks. The onset of effect was earlier in the steroid and botulinum toxin epic groups than in the botulinum toxin tend group.


Asunto(s)
Antiinflamatorios/uso terapéutico , Toxinas Botulínicas Tipo A/administración & dosificación , Fármacos Neuromusculares/administración & dosificación , Dolor/etiología , Codo de Tenista/tratamiento farmacológico , Triamcinolona Acetonida/uso terapéutico , Adulto , Método Doble Ciego , Femenino , Fuerza de la Mano , Humanos , Inyecciones Intraarticulares , Inyecciones Intramusculares , Masculino , Persona de Mediana Edad , Dimensión del Dolor , Proyectos Piloto , Codo de Tenista/complicaciones , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA